Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — September 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bibob
    wrote on sidst redigeret af
    #948

    Nice E L. New field for Genmab isn't it. ??

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #949

      they had a partnership with a small Danish company looooong time ago in infectious diseases, not even sure if that company still exists lol

      1 Reply Last reply
      0
      • P Offline
        P Offline
        peter12
        wrote on sidst redigeret af
        #950

        ACE Biosciences acc to google. Genmab mention infectious disease when describing Duobody platform. Did they cooperate with Amgen about something similar ?

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #951

          Faldt lidt tilfældigt over denne gamle nyhed, som jeg ikke havde hørt om før: Tavotek Biotherapeutics Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab’s Proprietary DuoBody® Technology Platform against a Pair of Disease Relevant Targets

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #952

            Link Preview Image
            Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets

            /PRNewswire/ -- Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered...

            favicon

            (www.prnewswire.com)

            1 Reply Last reply
            0
            • P Offline
              P Offline
              peter12
              wrote on sidst redigeret af
              #953

              Den har været nævnt her før men lyder spændende

              1 Reply Last reply
              0
              • P Offline
                P Offline
                Plimsoller
                wrote on sidst redigeret af
                #954

                God morgen 🙂

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #955

                  God morgen. 🙂

                  1 Reply Last reply
                  0
                  • M Offline
                    M Offline
                    Mogan
                    wrote on sidst redigeret af
                    #956

                    God morgen 🙂

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Stroka
                      wrote on sidst redigeret af
                      #957

                      Ikke megen chat i dag. Kursen klarer sig heldigvis fint uden. 🙂

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #958

                        DAX går pænt amok: https://www.proinvestor.com/investornyt/667649/dax-future-brager-op-gennem-12800-nu-3-i-dag

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #959

                          Large new ECOG-ACRIN trial, Dara Len Dex, adding Bortezomib in the consolidation phase only https://clinicaltrials.gov/ct2/show/NCT04566328?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody&lupd_s=09%2F28%2F2020&draw=2&rank=3

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #960

                            A third wing of the biotech is working on protein-based therapies, including in programs that pair its technology with the potentially complementary capabilities of CRISPR Therapeutics and Genmab.

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #961

                              Just a moment...

                              favicon

                              (www.fiercebiotech.com)

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bibob
                                wrote on sidst redigeret af
                                #962

                                Det var vel slet ikk så ring en daw. 😉

                                1 Reply Last reply
                                0
                                • nohopeN Offline
                                  nohopeN Offline
                                  nohope
                                  wrote on sidst redigeret af
                                  #963

                                  Lidt har også ret.

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #964

                                    Det er super positivt, at vi nærmer os 2400. Der er ganske pæn underliggende styrke. Gad nok vide hvem der maser på og med hvilken begrundelse, som ikke analytikerne har fået øje på.

                                    1 Reply Last reply
                                    0
                                    • T Offline
                                      T Offline
                                      transalp
                                      wrote on sidst redigeret af
                                      #965

                                      Go morgen.. 🙂

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        bibob
                                        wrote on sidst redigeret af
                                        #966

                                        God morgen. :-). FDA has granted PR for bb2121. https://www.onclive.com/view/fda-grants-priority-review-to-ide-cel-for-multiple-myeloma?utm_source=sfmc&utm_medium=email&utm_campaign=9-28-20_GIL-20-OGD0761_OncLiveSS_NHL CC eNews_Zydelig,Gilead_NON_US_Send&eKey=

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #967

                                          Vincent Rajkumar
                                          @VincentRK
                                          Just out: Current Treatment Algorithms for Multiple Myeloma. Concise Guide to Treatment in Open Access Resource. Blood Cancer Journal. #BCJ @myelomaMD
                                          @MayoClinic
                                          @mtmdphd
                                          @MayoCancerCare
                                          @Rfonsi1
                                          @NorthTxMSG
                                          #myelomaVR

                                          Full Text: https://nature.com/articles/s41408-020-00359-2

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger